STRATA Skin Sciences (SSKN) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue grew 10% year-over-year to $9.6 million, with strong international equipment sales and improved device utilization.

• Strategic focus on cost efficiency, device redeployment, and international expansion led to improved gross margin and operating metrics.

• Direct-to-consumer advertising generated 2,800 patient appointments in 2024.

• Underperforming accounts were removed, and support for high-volume clinics increased.

Financial highlights

• Q4 2024 total revenue was $9.6M, up 10% year-over-year from $8.7M.

• Gross profit increased to $5.8M from $4.8M in Q4 2023; gross margin improved to 60.1% from 55.3%.

• Q4 net loss was $4.5M (EPS: -$1.18), compared to $3.8M (EPS: -$1.09) in Q4 2023.

• Adjusted EBITDA for 2024 improved to $2.2M from $1.0M in 2023.

• Cash, cash equivalents, and restricted cash totaled $8.6M at year-end 2024.

Outlook and guidance

• Expects continued improvement in device utilization, international growth, and cost efficiency.

• Capex spend for 2025 projected to decline 67% year-over-year due to device removal and refurbishment.

• Noted strong seasonal effect: Q1 typically weaker than Q4, with historical sequential declines of 22–29%.

• Confident in executing 2025 strategic goals with current financial position.